References
- Adams F. G., Shirley A. W. Factors influencing bone scan quality. Eur. J. Nucl. Med. 1983; 8: 436
- B&K Universal, Sollentuna, Sweden. 1997, Personal communication
- Bonn D. Parathyroid hormone for osteoporosis. Lancet 1996; 347: 50
- Calvo M. S., Kumar R., Heath H., III. Elevated secretion and action of serum parathyroid hormone in young adults consuming high phosphorus, low calcium diets assembled from common foods. J. Clin. Endocrinol. Metab. 1988; 66: 823
- Charkes N. D., Makler P. T., Jr. Studies in skeletal tracer kinetics. V: Computer-simulated Tc-99m(Sn)MDP bone-scan changes in some systemic disorders. Concise communication. J. Nucl. Med. 1981; 22: 601
- Cronhjort M., Jonsson C., Nilsson S.-O., Garmelius B., Jacobsson H. Activity in the gastrointestinal tract after administration of bone-seeking radiopharmaceuticals. Experimental studies in mice. Acta Radiol. 1996; 37: 785
- Cronhjort M., Sjöberg H. E., Schnell P. O., Jacobsson H. Interaction between 99Tcm-hydroxymethylene diphosphonate and loop-diuretics in an experimental mouse system. Radiol. Diagnost. 1994; 35: 101
- Festing M. F. W. The scope for improving the design of laboratory animal experiments. Lab. Anim. 1992; 26: 256
- Finkelstein J. S., Klibanski A., Schaefer E. H., Hornstein M. D., Schiff I., Neer R. M. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N. Engl. J. Med. 1994; 331: 1618
- Fleisch H. Bisphosphonates. A new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res. 1989; 116: 1
- Fleisch H. Bisphosphonates — preclinical. Bisphosphonates in bone disease3rd edn. Parthenon Publishing, New York 1997; 32–67, From the laboratory to the patient
- Fogelman I. 99mTc diphosphonate bone-scanning agents. Bone scanning in clinical practice, I. Fogelman. Springer-Verlag, London 1987; 31–40
- Hladik W. B., III, Nigg K. K., Rhodes B. A. Druginduced changes in the biologic distribution of radiopharmaceuticals. Semin. Nucl. Med. 1982; 12: 184
- Knapka J. Nutrition. The mouse in biomedical research, H. L. Foster, et al. Academic Press, New York 1983; 51–68
- Lin J. H., Chen I. W., Deluna F. A., Hichens M. Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab. Dispos. 1992; 20: 608
- Lobaugh B. Blood calcium and phosphorus regulation. Calcium and phosphorus in health and disease, J. Anderson, S. Garner. CRC Press, Boca Raton 1996; 27–43
- Miller S. C., de Saint-Georges L., Bowman B. M., Jee W. S. Bone lining cells. Structure and function. Scan. Microsc. 1989; 3: 953
- Potts J. T., Jr, Tregear G. W., Keutmann H. T., et al. Synthesis of a biologically active N-terminal tetratriaconta peptide of parathyroid hormone. Proc. Natl. Acad. Sci. 1971; 68: 63
- Rosen C., Kessenich C. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Drugs 1996; 51: 537
- Sy W. M. Bone scan in primary hyperparathyroidism. J. Nucl. Med. 1974; 15: 1089
- Wang H. H., Drugge E. D., Yen Y. C., Blumenthal M. R., Pang P. K. Effects of synthetic parathyroid hormone on hemodynamics and regional blood flows. Eur. J. Pharmacol. 1984; 97: 209
- Wilson M. The effect of age on the quality of bone scans using technetium-99m pyrophosphate. Radiology 1981; 139: 703